Shares of Myriad Genetics (NASDAQ:MYGN) were unchanged in after-market trading after the company reported Q2 results.
Earnings per share decreased 152.17% over the past year to ($0.12), which were in line with the estimate of ($0.12).
Revenue of $154,600,000 declined by 20.76% from the same period last year, which beat the estimate of $150,390,000.
Earnings guidance hasn't been issued by the company for now.
Myriad Genetics hasn't issued ...
Full story available on Benzinga.com